COSCIENS Biopharma Inc T.AEZS

RE:RE:Avenanthramide and VCAM-1

[prophetoffactz]

Based on the provided search results, avenanthramides offer several potential benefits beyond lowering VCAM-1 for treating cardiovascular disease:

Anti-inflammatory Effects

Avenanthramides inhibit the expression of inflammatory molecules like NF-κB, COX-2, and pro-inflammatory cytokines TNF-α and IL-6, which can help reduce chronic inflammation in arterial walls, a key factor in atherosclerosis development.

Improved Glucose Metabolism

Some studies suggest avenanthramides may improve glucose control and insulin sensitivity, beneficial for individuals with diabetes or metabolic syndrome who are at higher cardiovascular disease risk.

Antioxidant Activity

Avenanthramides have strong antioxidant capabilities, neutralizing harmful free radicals and oxidative stress that contribute to endothelial dysfunction and atherosclerosis progression.Regarding impregnating avenanthramides into Ceapro's PGX yeast beta glucan (YBG), it could potentially enhance efficacy through synergistic effects:

1. The anti-inflammatory and antioxidant properties of avenanthramides could complement the immune-modulating effects of YBG, providing a multi-targeted approach to reducing inflammation and oxidative stress in cardiovascular disease.
2. Ceapro's PGX Technology allows for efficient loading of bioactive compounds like avenanthramides into the porous structure of YBG, potentially improving bioavailability and targeted delivery.
3. The combination could leverage the cholesterol-lowering and cardiovascular benefits of both YBG and avenanthramides, offering a comprehensive approach to managing multiple risk factors.

Ceapro is actively working on scaling up its PGX Technology for YBG production and standardizing specifications, with plans to potentially launch an immune-boosting YBG product by the end of 2024, subject to regulatory approvals. Impregnating avenanthramides into this YBG platform could create a novel, synergistic nutraceutical or pharmaceutical product for cardiovascular disease management.